19:55 , Jun 27, 2018 |  BC Extra  |  Preclinical News

Targeting a GPCR for alcohol addiction

Researchers at The Scripps Research Institute identified a GPCR in a brain region associated with drug and alcohol addiction as a new molecular target that could help treat alcohol abuse. In a paper published in eNeuro,...
23:07 , Jun 5, 2018 |  BC Extra  |  Company News

Management tracks: Sarepta, Gilead

Neuromuscular disease company Sarepta Therapeutics Inc. (NASDAQ:SRPT) hired Louise Rodino-Klapac as VP of gene therapy at its newly created gene therapy unit. She will continue to serve as acting CSO at Myonexus Therapeutics Inc. (New...
23:43 , May 31, 2018 |  BC Innovations  |  Emerging Company Profile

Oral route for HAE

The team behind Firazyr icatibant has reunited to develop an oral version of the drug that could give hereditary angioedema patients the alternative to injectables they’ve been asking for. Pharvaris B.V. brings together team members responsible...
12:03 , May 9, 2018 |  BC Extra  |  Financial News

Column Group leads Escient's $40M series A

Escient Pharmaceuticals Inc. (San Diego, Calif.) raised $40 million in a series A round led by The Column Group. Also participating were 5AM Ventures and Osage University Partners. Escient is developing compounds targeting GPCRs, including from...
22:00 , Mar 22, 2018 |  BC Innovations  |  Strategy

Janssen’s virtual discovery

In the latest example of how AI can accelerate drug discovery, Janssen has shown it can use machine learning to create virtual drug screens that outperform conventional assays. The most promising application may be in...
16:33 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Berlin Cures' heart failure candidate well tolerated in Phase I

Berlin Cures Holding AG (Zug, Switzerland) reported data from a Phase I trial in 68 healthy volunteers showing that a single IV infusion of heart failure candidate BC007 was well tolerated and eliminated autoantibodies against...
23:07 , Feb 8, 2018 |  BC Innovations  |  Finance

External rethink

As the industry seeks to develop new ways to access external innovation, companies are re-evaluating the value of public-private partnerships, and increasingly turning to other companies for research partnerships in lieu of broad deals with...
23:13 , Jan 25, 2018 |  BC Innovations  |  Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
22:30 , Jan 19, 2018 |  BC Extra  |  Company News

Management tracks: Shire, Sosei

Thomas Dittrich will become CFO, a director and a member of the executive committee of Shire plc (LSE: SHP, NASDAQ: SHPG) on March 19. The company announced his hiring in November. GPCR developer Sosei Group Corp....
00:16 , Dec 22, 2017 |  BC Week In Review  |  Company News

Confo in GPCRs deals with Roche, Lundbeck

Confo Therapeutics N.V. (Brussels, Belgium) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to its small molecule agonists against an undisclosed GPCR. Confo will receive a total of €6 million ($7.1 million) over 30 months, including an...